Autonomous Trucks
Using TipRanks’ database, we found out that the rest of the Street is also on board, as each boasts a “Strong Buy” consensus rating. Rain Therapeutics (RAIN) We’ll start with a newly public biopharmaceutical company Rain Therapeutics. As only Buy recommendations have been published in the last three months, RAIN earns a Strong Buy analyst consensus. 3 Buys and no Holds or Sells add up to a Strong Buy consensus rating. Given the $67.67 average price target, shares could climb 76% in the year ahead.